nodes	percent_of_prediction	percent_of_DWPC	metapath
Isoprenaline—CYP1A1—Dacarbazine—sarcoma	0.034	1	CbGbCtD
Isoprenaline—PIK3R3—mammary gland—sarcoma	0.0139	0.0741	CbGeAlD
Isoprenaline—PIK3R1—mammary gland—sarcoma	0.0118	0.0633	CbGeAlD
Isoprenaline—Masoprocol—IGF1R—sarcoma	0.00847	1	CrCbGaD
Isoprenaline—PIK3R1—myometrium—sarcoma	0.00839	0.0449	CbGeAlD
Isoprenaline—ADRBK1—mammary gland—sarcoma	0.00819	0.0438	CbGeAlD
Isoprenaline—MAPK1—mammary gland—sarcoma	0.00807	0.0432	CbGeAlD
Isoprenaline—PIK3R3—uterus—sarcoma	0.00637	0.0341	CbGeAlD
Isoprenaline—ADRBK1—embryo—sarcoma	0.00559	0.0299	CbGeAlD
Isoprenaline—PIK3R3—tendon—sarcoma	0.00558	0.0299	CbGeAlD
Isoprenaline—MAPK1—embryo—sarcoma	0.00551	0.0295	CbGeAlD
Isoprenaline—PIK3R1—cardiac atrium—sarcoma	0.00547	0.0293	CbGeAlD
Isoprenaline—PIK3R1—uterus—sarcoma	0.00544	0.0291	CbGeAlD
Isoprenaline—ADRBK1—hematopoietic system—sarcoma	0.00499	0.0267	CbGeAlD
Isoprenaline—MAPK1—hematopoietic system—sarcoma	0.00492	0.0263	CbGeAlD
Isoprenaline—ADRB3—connective tissue—sarcoma	0.00491	0.0263	CbGeAlD
Isoprenaline—PIK3R1—tendon—sarcoma	0.00477	0.0255	CbGeAlD
Isoprenaline—MAPK1—connective tissue—sarcoma	0.00473	0.0253	CbGeAlD
Isoprenaline—PIK3R3—testis—sarcoma	0.00462	0.0248	CbGeAlD
Isoprenaline—PIK3R1—bone marrow—sarcoma	0.00462	0.0247	CbGeAlD
Isoprenaline—ADRBK1—smooth muscle tissue—sarcoma	0.00439	0.0235	CbGeAlD
Isoprenaline—MAPK1—smooth muscle tissue—sarcoma	0.00433	0.0232	CbGeAlD
Isoprenaline—MAPK1—skin of body—sarcoma	0.00427	0.0229	CbGeAlD
Isoprenaline—PIK3R1—testis—sarcoma	0.00395	0.0211	CbGeAlD
Isoprenaline—Tachyarrhythmia—Epirubicin—sarcoma	0.00393	0.0742	CcSEcCtD
Isoprenaline—PIK3R1—liver—sarcoma	0.00373	0.02	CbGeAlD
Isoprenaline—MAPK1—cardiac atrium—sarcoma	0.00373	0.02	CbGeAlD
Isoprenaline—MAPK1—uterus—sarcoma	0.00371	0.0199	CbGeAlD
Isoprenaline—Tachyarrhythmia—Doxorubicin—sarcoma	0.00363	0.0686	CcSEcCtD
Isoprenaline—ADRBK1—lymphoid tissue—sarcoma	0.00351	0.0188	CbGeAlD
Isoprenaline—MAPK1—lymphoid tissue—sarcoma	0.00346	0.0185	CbGeAlD
Isoprenaline—PIK3R3—lymph node—sarcoma	0.00335	0.0179	CbGeAlD
Isoprenaline—ADRBK1—bone marrow—sarcoma	0.0032	0.0171	CbGeAlD
Isoprenaline—MAPK1—bone marrow—sarcoma	0.00315	0.0169	CbGeAlD
Isoprenaline—PIK3R1—lymph node—sarcoma	0.00286	0.0153	CbGeAlD
Isoprenaline—ADRBK1—testis—sarcoma	0.00273	0.0146	CbGeAlD
Isoprenaline—MAPK1—testis—sarcoma	0.00269	0.0144	CbGeAlD
Isoprenaline—MAPK1—liver—sarcoma	0.00255	0.0136	CbGeAlD
Isoprenaline—ADRB1—connective tissue—sarcoma	0.00201	0.0108	CbGeAlD
Isoprenaline—ADRBK1—lymph node—sarcoma	0.00198	0.0106	CbGeAlD
Isoprenaline—MAPK1—lymph node—sarcoma	0.00195	0.0105	CbGeAlD
Isoprenaline—Pulmonary oedema—Thiotepa—sarcoma	0.00158	0.03	CcSEcCtD
Isoprenaline—ADRB1—cardiac atrium—sarcoma	0.00158	0.00848	CbGeAlD
Isoprenaline—CYP1A1—hematopoietic system—sarcoma	0.00135	0.0072	CbGeAlD
Isoprenaline—Cardiac arrest—Thiotepa—sarcoma	0.00123	0.0232	CcSEcCtD
Isoprenaline—CYP1A1—skin of body—sarcoma	0.00117	0.00626	CbGeAlD
Isoprenaline—Cardiac arrest—Vincristine—sarcoma	0.00109	0.0206	CcSEcCtD
Isoprenaline—CYP1A1—cardiac atrium—sarcoma	0.00102	0.00547	CbGeAlD
Isoprenaline—CYP1A1—uterus—sarcoma	0.00102	0.00544	CbGeAlD
Isoprenaline—Ventricular arrhythmia—Epirubicin—sarcoma	0.000969	0.0183	CcSEcCtD
Isoprenaline—Ventricular arrhythmia—Doxorubicin—sarcoma	0.000896	0.0169	CcSEcCtD
Isoprenaline—Cardiac arrest—Etoposide—sarcoma	0.000883	0.0167	CcSEcCtD
Isoprenaline—Sweating—Vincristine—sarcoma	0.000847	0.016	CcSEcCtD
Isoprenaline—Sweating—Mitoxantrone—sarcoma	0.000825	0.0156	CcSEcCtD
Isoprenaline—Flushing—Dactinomycin—sarcoma	0.000824	0.0156	CcSEcCtD
Isoprenaline—Arrhythmia—Thiotepa—sarcoma	0.000799	0.0151	CcSEcCtD
Isoprenaline—Bronchospasm—Etoposide—sarcoma	0.000789	0.0149	CcSEcCtD
Isoprenaline—Tension—Thiotepa—sarcoma	0.000764	0.0144	CcSEcCtD
Isoprenaline—Nervousness—Thiotepa—sarcoma	0.000756	0.0143	CcSEcCtD
Isoprenaline—Vision blurred—Thiotepa—sarcoma	0.000734	0.0139	CcSEcCtD
Isoprenaline—CYP1A1—liver—sarcoma	0.000697	0.00373	CbGeAlD
Isoprenaline—Arrhythmia—Mitoxantrone—sarcoma	0.00069	0.013	CcSEcCtD
Isoprenaline—Convulsion—Thiotepa—sarcoma	0.000674	0.0127	CcSEcCtD
Isoprenaline—Hypertension—Thiotepa—sarcoma	0.000672	0.0127	CcSEcCtD
Isoprenaline—Pulmonary oedema—Epirubicin—sarcoma	0.000638	0.0121	CcSEcCtD
Isoprenaline—Vision blurred—Mitoxantrone—sarcoma	0.000633	0.012	CcSEcCtD
Isoprenaline—Vertigo—Vincristine—sarcoma	0.00062	0.0117	CcSEcCtD
Isoprenaline—Tachycardia—Thiotepa—sarcoma	0.00062	0.0117	CcSEcCtD
Isoprenaline—Convulsion—Vincristine—sarcoma	0.000598	0.0113	CcSEcCtD
Isoprenaline—Flushing—Etoposide—sarcoma	0.000596	0.0113	CcSEcCtD
Isoprenaline—Hypertension—Vincristine—sarcoma	0.000596	0.0113	CcSEcCtD
Isoprenaline—Pulmonary oedema—Doxorubicin—sarcoma	0.00059	0.0112	CcSEcCtD
Isoprenaline—Convulsion—Mitoxantrone—sarcoma	0.000582	0.011	CcSEcCtD
Isoprenaline—Hypertension—Mitoxantrone—sarcoma	0.00058	0.011	CcSEcCtD
Isoprenaline—Hyperhidrosis—Vincristine—sarcoma	0.000545	0.0103	CcSEcCtD
Isoprenaline—Tachycardia—Mitoxantrone—sarcoma	0.000535	0.0101	CcSEcCtD
Isoprenaline—CYP1A1—lymph node—sarcoma	0.000535	0.00286	CbGeAlD
Isoprenaline—Hyperhidrosis—Mitoxantrone—sarcoma	0.00053	0.01	CcSEcCtD
Isoprenaline—Hypotension—Vincristine—sarcoma	0.000526	0.00995	CcSEcCtD
Isoprenaline—Hypotension—Mitoxantrone—sarcoma	0.000513	0.00969	CcSEcCtD
Isoprenaline—Insomnia—Vincristine—sarcoma	0.000509	0.00963	CcSEcCtD
Isoprenaline—Vertigo—Etoposide—sarcoma	0.000502	0.00949	CcSEcCtD
Isoprenaline—Cardiac arrest—Epirubicin—sarcoma	0.000495	0.00935	CcSEcCtD
Isoprenaline—Dyspnoea—Mitoxantrone—sarcoma	0.000489	0.00924	CcSEcCtD
Isoprenaline—Convulsion—Etoposide—sarcoma	0.000484	0.00916	CcSEcCtD
Isoprenaline—Hypertension—Etoposide—sarcoma	0.000483	0.00912	CcSEcCtD
Isoprenaline—Cardiac arrest—Doxorubicin—sarcoma	0.000458	0.00865	CcSEcCtD
Isoprenaline—Asthenia—Thiotepa—sarcoma	0.000456	0.00861	CcSEcCtD
Isoprenaline—Asthenia—Dactinomycin—sarcoma	0.000452	0.00855	CcSEcCtD
Isoprenaline—Tachycardia—Etoposide—sarcoma	0.000445	0.00842	CcSEcCtD
Isoprenaline—Hyperhidrosis—Etoposide—sarcoma	0.000441	0.00834	CcSEcCtD
Isoprenaline—Angina pectoris—Epirubicin—sarcoma	0.000438	0.00828	CcSEcCtD
Isoprenaline—Hypotension—Etoposide—sarcoma	0.000426	0.00806	CcSEcCtD
Isoprenaline—Dizziness—Thiotepa—sarcoma	0.00042	0.00794	CcSEcCtD
Isoprenaline—Dyspnoea—Etoposide—sarcoma	0.000407	0.00769	CcSEcCtD
Isoprenaline—Angina pectoris—Doxorubicin—sarcoma	0.000405	0.00766	CcSEcCtD
Isoprenaline—Asthenia—Vincristine—sarcoma	0.000404	0.00764	CcSEcCtD
Isoprenaline—Headache—Thiotepa—sarcoma	0.000398	0.00752	CcSEcCtD
Isoprenaline—Asthenia—Mitoxantrone—sarcoma	0.000394	0.00744	CcSEcCtD
Isoprenaline—Sweating—Epirubicin—sarcoma	0.000384	0.00727	CcSEcCtD
Isoprenaline—Nausea—Thiotepa—sarcoma	0.000377	0.00713	CcSEcCtD
Isoprenaline—Nausea—Dactinomycin—sarcoma	0.000375	0.00708	CcSEcCtD
Isoprenaline—Dizziness—Vincristine—sarcoma	0.000373	0.00704	CcSEcCtD
Isoprenaline—Sweating—Doxorubicin—sarcoma	0.000356	0.00672	CcSEcCtD
Isoprenaline—Headache—Vincristine—sarcoma	0.000353	0.00667	CcSEcCtD
Isoprenaline—Headache—Mitoxantrone—sarcoma	0.000344	0.0065	CcSEcCtD
Isoprenaline—Nausea—Vincristine—sarcoma	0.000335	0.00632	CcSEcCtD
Isoprenaline—Flushing—Epirubicin—sarcoma	0.000334	0.00632	CcSEcCtD
Isoprenaline—Asthenia—Etoposide—sarcoma	0.000327	0.00619	CcSEcCtD
Isoprenaline—Nausea—Mitoxantrone—sarcoma	0.000326	0.00616	CcSEcCtD
Isoprenaline—Arrhythmia—Epirubicin—sarcoma	0.000322	0.00608	CcSEcCtD
Isoprenaline—Flushing—Doxorubicin—sarcoma	0.000309	0.00584	CcSEcCtD
Isoprenaline—Tension—Epirubicin—sarcoma	0.000308	0.00581	CcSEcCtD
Isoprenaline—Nervousness—Epirubicin—sarcoma	0.000304	0.00575	CcSEcCtD
Isoprenaline—Dizziness—Etoposide—sarcoma	0.000302	0.0057	CcSEcCtD
Isoprenaline—Arrhythmia—Doxorubicin—sarcoma	0.000298	0.00562	CcSEcCtD
Isoprenaline—Vision blurred—Epirubicin—sarcoma	0.000295	0.00558	CcSEcCtD
Isoprenaline—Headache—Etoposide—sarcoma	0.000286	0.0054	CcSEcCtD
Isoprenaline—Tension—Doxorubicin—sarcoma	0.000285	0.00538	CcSEcCtD
Isoprenaline—Nervousness—Doxorubicin—sarcoma	0.000282	0.00532	CcSEcCtD
Isoprenaline—Vertigo—Epirubicin—sarcoma	0.000282	0.00532	CcSEcCtD
Isoprenaline—Palpitations—Epirubicin—sarcoma	0.000277	0.00523	CcSEcCtD
Isoprenaline—Vision blurred—Doxorubicin—sarcoma	0.000273	0.00517	CcSEcCtD
Isoprenaline—Convulsion—Epirubicin—sarcoma	0.000272	0.00513	CcSEcCtD
Isoprenaline—Nausea—Etoposide—sarcoma	0.000271	0.00512	CcSEcCtD
Isoprenaline—Hypertension—Epirubicin—sarcoma	0.000271	0.00511	CcSEcCtD
Isoprenaline—Vertigo—Doxorubicin—sarcoma	0.000261	0.00492	CcSEcCtD
Isoprenaline—Palpitations—Doxorubicin—sarcoma	0.000256	0.00484	CcSEcCtD
Isoprenaline—Convulsion—Doxorubicin—sarcoma	0.000251	0.00475	CcSEcCtD
Isoprenaline—Hypertension—Doxorubicin—sarcoma	0.00025	0.00473	CcSEcCtD
Isoprenaline—Tachycardia—Epirubicin—sarcoma	0.00025	0.00472	CcSEcCtD
Isoprenaline—Hyperhidrosis—Epirubicin—sarcoma	0.000247	0.00467	CcSEcCtD
Isoprenaline—Hypotension—Epirubicin—sarcoma	0.000239	0.00452	CcSEcCtD
Isoprenaline—Insomnia—Epirubicin—sarcoma	0.000231	0.00437	CcSEcCtD
Isoprenaline—Tachycardia—Doxorubicin—sarcoma	0.000231	0.00437	CcSEcCtD
Isoprenaline—Hyperhidrosis—Doxorubicin—sarcoma	0.000229	0.00432	CcSEcCtD
Isoprenaline—Dyspnoea—Epirubicin—sarcoma	0.000228	0.00431	CcSEcCtD
Isoprenaline—Hypotension—Doxorubicin—sarcoma	0.000221	0.00418	CcSEcCtD
Isoprenaline—Insomnia—Doxorubicin—sarcoma	0.000214	0.00405	CcSEcCtD
Isoprenaline—Dyspnoea—Doxorubicin—sarcoma	0.000211	0.00399	CcSEcCtD
Isoprenaline—Asthenia—Epirubicin—sarcoma	0.000184	0.00347	CcSEcCtD
Isoprenaline—Asthenia—Doxorubicin—sarcoma	0.00017	0.00321	CcSEcCtD
Isoprenaline—Dizziness—Epirubicin—sarcoma	0.000169	0.0032	CcSEcCtD
Isoprenaline—Headache—Epirubicin—sarcoma	0.00016	0.00303	CcSEcCtD
Isoprenaline—Dizziness—Doxorubicin—sarcoma	0.000157	0.00296	CcSEcCtD
Isoprenaline—Nausea—Epirubicin—sarcoma	0.000152	0.00287	CcSEcCtD
Isoprenaline—Headache—Doxorubicin—sarcoma	0.000148	0.0028	CcSEcCtD
Isoprenaline—Nausea—Doxorubicin—sarcoma	0.000141	0.00266	CcSEcCtD
Isoprenaline—PIK3R3—Signaling by GPCR—HRAS—sarcoma	2.8e-05	3.91e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Immune System—NRAS—sarcoma	2.79e-05	3.89e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—MDM2—sarcoma	2.78e-05	3.88e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling by GPCR—EGFR—sarcoma	2.78e-05	3.88e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Disease—KRAS—sarcoma	2.78e-05	3.88e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Immune System—NRAS—sarcoma	2.75e-05	3.83e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Innate Immune System—SRC—sarcoma	2.74e-05	3.82e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling by GPCR—EGFR—sarcoma	2.74e-05	3.82e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Adaptive Immune System—HRAS—sarcoma	2.73e-05	3.8e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Developmental Biology—EGFR—sarcoma	2.72e-05	3.79e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—CREB1—sarcoma	2.71e-05	3.78e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—FLT1—sarcoma	2.7e-05	3.76e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—IL2—sarcoma	2.7e-05	3.76e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Immune System—IL2—sarcoma	2.69e-05	3.75e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—KDR—sarcoma	2.69e-05	3.74e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Disease—SRC—sarcoma	2.68e-05	3.73e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—PLCG1—sarcoma	2.65e-05	3.69e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—FLT1—sarcoma	2.64e-05	3.68e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Innate Immune System—NRAS—sarcoma	2.64e-05	3.68e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Disease—SRC—sarcoma	2.64e-05	3.68e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling by GPCR—KRAS—sarcoma	2.63e-05	3.66e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—CCND1—sarcoma	2.63e-05	3.66e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—JUN—sarcoma	2.62e-05	3.65e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—KDR—sarcoma	2.62e-05	3.65e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Immune System—JUN—sarcoma	2.62e-05	3.65e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—CTNNB1—sarcoma	2.6e-05	3.63e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—KIT—sarcoma	2.6e-05	3.63e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Immune System—CTNNB1—sarcoma	2.6e-05	3.62e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—PLCG1—sarcoma	2.59e-05	3.61e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling by GPCR—KRAS—sarcoma	2.59e-05	3.61e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Cell Cycle—MYC—sarcoma	2.58e-05	3.59e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Disease—NRAS—sarcoma	2.58e-05	3.59e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Developmental Biology—KRAS—sarcoma	2.57e-05	3.58e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Immune System—HRAS—sarcoma	2.56e-05	3.57e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—CXCR4—sarcoma	2.55e-05	3.55e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Immune System—EGFR—sarcoma	2.54e-05	3.54e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Disease—NRAS—sarcoma	2.54e-05	3.54e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Hemostasis—KRAS—sarcoma	2.52e-05	3.51e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—ATF1—sarcoma	2.52e-05	3.51e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Immune System—EGFR—sarcoma	2.5e-05	3.49e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—CXCR4—sarcoma	2.49e-05	3.47e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—CREB1—sarcoma	2.48e-05	3.45e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—KIT—sarcoma	2.48e-05	3.45e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling by GPCR—NRAS—sarcoma	2.48e-05	3.45e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—ATF1—sarcoma	2.46e-05	3.43e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—ENO2—sarcoma	2.43e-05	3.39e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—HBA1—sarcoma	2.42e-05	3.37e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—KIT—sarcoma	2.42e-05	3.37e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling by GPCR—NRAS—sarcoma	2.42e-05	3.37e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—MDM2—sarcoma	2.41e-05	3.35e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Innate Immune System—EGFR—sarcoma	2.4e-05	3.35e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—KIT—sarcoma	2.4e-05	3.35e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Immune System—KRAS—sarcoma	2.4e-05	3.35e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—CTNNB1—sarcoma	2.4e-05	3.34e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Disease—MYC—sarcoma	2.4e-05	3.34e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—MDM2—sarcoma	2.37e-05	3.3e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Immune System—KRAS—sarcoma	2.37e-05	3.3e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Disease—HRAS—sarcoma	2.37e-05	3.29e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Disease—MYC—sarcoma	2.36e-05	3.29e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—CREB1—sarcoma	2.36e-05	3.28e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—SRC—sarcoma	2.35e-05	3.28e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Immune System—SRC—sarcoma	2.35e-05	3.27e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Disease—EGFR—sarcoma	2.35e-05	3.27e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—IGF1R—sarcoma	2.32e-05	3.23e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Disease—EGFR—sarcoma	2.31e-05	3.22e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—CREB1—sarcoma	2.31e-05	3.22e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—CREB1—sarcoma	2.3e-05	3.2e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—VEGFA—sarcoma	2.29e-05	3.19e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—CREB1—sarcoma	2.29e-05	3.19e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Innate Immune System—KRAS—sarcoma	2.27e-05	3.16e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—NRAS—sarcoma	2.26e-05	3.15e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Immune System—NRAS—sarcoma	2.26e-05	3.15e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—CREB1—sarcoma	2.26e-05	3.15e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling by GPCR—EGFR—sarcoma	2.26e-05	3.14e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Hemostasis—TP53—sarcoma	2.24e-05	3.12e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling by GPCR—HRAS—sarcoma	2.23e-05	3.11e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Disease—KRAS—sarcoma	2.22e-05	3.09e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—FOXO1—sarcoma	2.21e-05	3.08e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—PDGFRB—sarcoma	2.2e-05	3.07e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling by GPCR—HRAS—sarcoma	2.2e-05	3.07e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling by GPCR—EGFR—sarcoma	2.2e-05	3.07e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Developmental Biology—HRAS—sarcoma	2.19e-05	3.05e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Disease—KRAS—sarcoma	2.18e-05	3.04e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—SRC—sarcoma	2.17e-05	3.02e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—PDGFRA—sarcoma	2.17e-05	3.02e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—IL2—sarcoma	2.15e-05	2.99e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Hemostasis—HRAS—sarcoma	2.14e-05	2.99e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling by GPCR—KRAS—sarcoma	2.13e-05	2.97e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—IL2—sarcoma	2.12e-05	2.95e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Cell Cycle—TP53—sarcoma	2.12e-05	2.95e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—MYC—sarcoma	2.11e-05	2.94e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—CCND1—sarcoma	2.1e-05	2.92e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—JUN—sarcoma	2.09e-05	2.91e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—NRAS—sarcoma	2.09e-05	2.91e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling by GPCR—KRAS—sarcoma	2.08e-05	2.9e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—CTNNB1—sarcoma	2.08e-05	2.89e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PLCG1—sarcoma	2.06e-05	2.88e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—CCND1—sarcoma	2.06e-05	2.88e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—EGFR—sarcoma	2.06e-05	2.87e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Immune System—EGFR—sarcoma	2.06e-05	2.87e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—JUN—sarcoma	2.06e-05	2.87e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—MDM2—sarcoma	2.05e-05	2.86e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—CTNNB1—sarcoma	2.04e-05	2.85e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Immune System—HRAS—sarcoma	2.04e-05	2.84e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Immune System—HRAS—sarcoma	2.01e-05	2.8e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—IL2—sarcoma	2e-05	2.79e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—IGF1R—sarcoma	1.98e-05	2.75e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—MDM2—sarcoma	1.95e-05	2.72e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—KRAS—sarcoma	1.95e-05	2.71e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Immune System—KRAS—sarcoma	1.95e-05	2.71e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—MYC—sarcoma	1.94e-05	2.71e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—IGF1R—sarcoma	1.93e-05	2.69e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Innate Immune System—HRAS—sarcoma	1.93e-05	2.69e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—MDM2—sarcoma	1.9e-05	2.65e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—EGFR—sarcoma	1.9e-05	2.65e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—MDM2—sarcoma	1.89e-05	2.64e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Disease—HRAS—sarcoma	1.89e-05	2.63e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—FOXO1—sarcoma	1.88e-05	2.62e-05	CbGpPWpGaD
Isoprenaline—ADRB1—GPCR downstream signaling—IL2—sarcoma	1.88e-05	2.62e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—PDGFRB—sarcoma	1.88e-05	2.62e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—SRC—sarcoma	1.88e-05	2.61e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Disease—HRAS—sarcoma	1.86e-05	2.59e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—PDGFRA—sarcoma	1.85e-05	2.58e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—SRC—sarcoma	1.85e-05	2.57e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—FOXO1—sarcoma	1.84e-05	2.56e-05	CbGpPWpGaD
Isoprenaline—ADRB2—GPCR downstream signaling—IL2—sarcoma	1.84e-05	2.56e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—PDGFRB—sarcoma	1.84e-05	2.56e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—IL2—sarcoma	1.83e-05	2.55e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—VEGFA—sarcoma	1.83e-05	2.55e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—KDR—sarcoma	1.83e-05	2.54e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling by GPCR—HRAS—sarcoma	1.81e-05	2.52e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—PDGFRA—sarcoma	1.81e-05	2.52e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—NRAS—sarcoma	1.8e-05	2.51e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—VEGFA—sarcoma	1.8e-05	2.51e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—KRAS—sarcoma	1.8e-05	2.5e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—JUN—sarcoma	1.78e-05	2.48e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—NRAS—sarcoma	1.78e-05	2.48e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—CTNNB1—sarcoma	1.77e-05	2.46e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling by GPCR—HRAS—sarcoma	1.77e-05	2.46e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—IL2—sarcoma	1.74e-05	2.43e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—TP53—sarcoma	1.73e-05	2.41e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—IL2—sarcoma	1.71e-05	2.38e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—IL2—sarcoma	1.7e-05	2.37e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—CCND1—sarcoma	1.7e-05	2.37e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—JUN—sarcoma	1.69e-05	2.36e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—KIT—sarcoma	1.68e-05	2.34e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—NRAS—sarcoma	1.68e-05	2.34e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—CTNNB1—sarcoma	1.68e-05	2.34e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—MYC—sarcoma	1.68e-05	2.34e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—IL2—sarcoma	1.67e-05	2.33e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—CCND1—sarcoma	1.66e-05	2.31e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—HRAS—sarcoma	1.66e-05	2.31e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—MYC—sarcoma	1.66e-05	2.31e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Immune System—HRAS—sarcoma	1.65e-05	2.3e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—JUN—sarcoma	1.65e-05	2.3e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—EGFR—sarcoma	1.64e-05	2.29e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—CTNNB1—sarcoma	1.64e-05	2.29e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—CTNNB1—sarcoma	1.63e-05	2.27e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—EGFR—sarcoma	1.62e-05	2.26e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—CREB1—sarcoma	1.6e-05	2.23e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—SRC—sarcoma	1.6e-05	2.23e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—KDR—sarcoma	1.56e-05	2.17e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—KRAS—sarcoma	1.55e-05	2.16e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—NRAS—sarcoma	1.54e-05	2.14e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—EGFR—sarcoma	1.53e-05	2.14e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—KRAS—sarcoma	1.53e-05	2.13e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—HRAS—sarcoma	1.53e-05	2.13e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—KDR—sarcoma	1.52e-05	2.12e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—SRC—sarcoma	1.52e-05	2.12e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—SRC—sarcoma	1.48e-05	2.07e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—VEGFA—sarcoma	1.48e-05	2.06e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—SRC—sarcoma	1.48e-05	2.06e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—NRAS—sarcoma	1.46e-05	2.04e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—KRAS—sarcoma	1.45e-05	2.02e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—VEGFA—sarcoma	1.44e-05	2.01e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—KIT—sarcoma	1.43e-05	2e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—NRAS—sarcoma	1.43e-05	2e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—NRAS—sarcoma	1.43e-05	1.99e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—NRAS—sarcoma	1.42e-05	1.98e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—KIT—sarcoma	1.4e-05	1.95e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—NRAS—sarcoma	1.4e-05	1.95e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—EGFR—sarcoma	1.4e-05	1.95e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—TP53—sarcoma	1.38e-05	1.92e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—CREB1—sarcoma	1.36e-05	1.9e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—MYC—sarcoma	1.36e-05	1.9e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—TP53—sarcoma	1.36e-05	1.89e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—CREB1—sarcoma	1.34e-05	1.86e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—EGFR—sarcoma	1.33e-05	1.86e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—MYC—sarcoma	1.33e-05	1.85e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—MDM2—sarcoma	1.33e-05	1.85e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—KRAS—sarcoma	1.32e-05	1.84e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—MYC—sarcoma	1.32e-05	1.84e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—HRAS—sarcoma	1.32e-05	1.84e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—EGFR—sarcoma	1.31e-05	1.82e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—HRAS—sarcoma	1.3e-05	1.81e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—EGFR—sarcoma	1.3e-05	1.81e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—EGFR—sarcoma	1.29e-05	1.8e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—EGFR—sarcoma	1.28e-05	1.78e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—KRAS—sarcoma	1.26e-05	1.75e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—KRAS—sarcoma	1.23e-05	1.72e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—HRAS—sarcoma	1.23e-05	1.71e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—KRAS—sarcoma	1.23e-05	1.71e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—KRAS—sarcoma	1.22e-05	1.7e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—KRAS—sarcoma	1.21e-05	1.68e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—IL2—sarcoma	1.18e-05	1.65e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—CCND1—sarcoma	1.15e-05	1.61e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—JUN—sarcoma	1.15e-05	1.6e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—CTNNB1—sarcoma	1.14e-05	1.59e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—MDM2—sarcoma	1.13e-05	1.57e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—HRAS—sarcoma	1.12e-05	1.57e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—TP53—sarcoma	1.12e-05	1.56e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—MDM2—sarcoma	1.1e-05	1.54e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—TP53—sarcoma	1.09e-05	1.52e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—HRAS—sarcoma	1.07e-05	1.49e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—HRAS—sarcoma	1.05e-05	1.46e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—HRAS—sarcoma	1.04e-05	1.45e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—HRAS—sarcoma	1.04e-05	1.45e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—SRC—sarcoma	1.03e-05	1.44e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—HRAS—sarcoma	1.03e-05	1.43e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—IL2—sarcoma	1.01e-05	1.41e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—VEGFA—sarcoma	1.01e-05	1.4e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—NRAS—sarcoma	9.94e-06	1.38e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—IL2—sarcoma	9.87e-06	1.38e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—CCND1—sarcoma	9.84e-06	1.37e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—JUN—sarcoma	9.82e-06	1.37e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—CTNNB1—sarcoma	9.74e-06	1.36e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—CCND1—sarcoma	9.62e-06	1.34e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—JUN—sarcoma	9.6e-06	1.34e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—CTNNB1—sarcoma	9.53e-06	1.33e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—MYC—sarcoma	9.26e-06	1.29e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—EGFR—sarcoma	9.06e-06	1.26e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—SRC—sarcoma	8.8e-06	1.23e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—SRC—sarcoma	8.61e-06	1.2e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—VEGFA—sarcoma	8.58e-06	1.19e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—KRAS—sarcoma	8.55e-06	1.19e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—NRAS—sarcoma	8.47e-06	1.18e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—VEGFA—sarcoma	8.39e-06	1.17e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—NRAS—sarcoma	8.29e-06	1.15e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—MYC—sarcoma	7.89e-06	1.1e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—MYC—sarcoma	7.72e-06	1.08e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—EGFR—sarcoma	7.72e-06	1.08e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—TP53—sarcoma	7.6e-06	1.06e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—EGFR—sarcoma	7.55e-06	1.05e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—KRAS—sarcoma	7.29e-06	1.02e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—HRAS—sarcoma	7.27e-06	1.01e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—KRAS—sarcoma	7.13e-06	9.93e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—TP53—sarcoma	6.48e-06	9.03e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—TP53—sarcoma	6.34e-06	8.83e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—HRAS—sarcoma	6.2e-06	8.63e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—HRAS—sarcoma	6.06e-06	8.44e-06	CbGpPWpGaD
